11.74
3.62%
0.41
After Hours:
11.77
0.03
+0.26%
Amicus Therapeutics Inc stock is traded at $11.74, with a volume of 1.96M.
It is up +3.62% in the last 24 hours and up +10.75% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$11.33
Open:
$11.24
24h Volume:
1.96M
Relative Volume:
0.81
Market Cap:
$3.48B
Revenue:
$423.49M
Net Income/Loss:
$-147.07M
P/E Ratio:
-18.34
EPS:
-0.64
Net Cash Flow:
$-88.03M
1W Performance:
+2.18%
1M Performance:
+10.75%
6M Performance:
+12.88%
1Y Performance:
+1.38%
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(215) 921-7600
Address
3675 MARKET STREET, PHILADELPHIA, NJ
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-06-24 | Initiated | Jefferies | Buy |
May-30-24 | Initiated | Wells Fargo | Overweight |
May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
Apr-13-22 | Resumed | Goldman | Neutral |
Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Nov-15-21 | Upgrade | Stifel | Hold → Buy |
Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-19-21 | Resumed | BTIG Research | Buy |
May-27-21 | Initiated | Needham | Hold |
May-21-21 | Initiated | UBS | Buy |
Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-02-21 | Initiated | Stifel | Hold |
Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
Nov-11-20 | Initiated | Berenberg | Hold |
Jun-17-20 | Initiated | BTIG Research | Buy |
Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
Jun-17-19 | Initiated | H.C. Wainwright | Buy |
Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
Apr-05-19 | Initiated | Janney | Buy |
Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
Oct-29-18 | Initiated | Citigroup | Neutral |
Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
May-18-16 | Initiated | BofA/Merrill | Buy |
Apr-14-16 | Initiated | Robert W. Baird | Neutral |
Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - Yahoo Finance
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday - MarketBeat
Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy - Defense World
Pompe Disease Market on Track for Major Expansion by 2034, - openPR
Pompe Disease Market on Track for Major Expansion by 2034, According to DelveInsight | Asklepios Biopharma, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark - The Globe and Mail
(FOLD) Proactive Strategies - Stock Traders Daily
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of America - Defense World
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% - MSN
Creative Planning Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
What is Zacks Research’s Estimate for FOLD Q3 Earnings? - Defense World
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - MSN
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva - MSN
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Teva settles patent litigation with Amicus (TEVA:NYSE) - Seeking Alpha
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Zacks Research Issues Optimistic Outlook for FOLD Earnings - MarketBeat
What is Zacks Research’s Estimate for FOLD Q2 Earnings? - Defense World
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva - GlobeNewswire
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpHere's Why - MarketBeat
Amicus announces settlement of Galafold patent litigation with Teva - TipRanks
Amicus Therapeutics settles patent litigation with Teva - Investing.com
Amicus Therapeutics settles patent litigation with Teva By Investing.com - Investing.com Australia
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance
Amicus Therapeutics Shares Rise After Lawsuit Settlement, Deal With Teva - MarketWatch
Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research Forecasts - MarketBeat
SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Taking on analysts’ expectations and winning: Amicus Therapeutics Inc (FOLD) - SETE News
Morgan Stanley Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $18.00 - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Cut to Hold at StockNews.com - MarketBeat
Gaucher’s Disease Treatment Industry to Witness an Outstanding Growth by 2034 |Amicus Therapeutics, Inc., Novartis AG, S – IndiaPolitics.com - IndiaPolitics.com
Analyzing Amicus Therapeutics Inc (FOLD) After Recent Trading Activity - Knox Daily
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):